Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Oscar Soto Raices

Rheumatology San Juan, PR Medical Doctor

NPI 1962441717 CMS profile 179451

576 Calle Cesar Gonzalez, Suite 101 A, San Juan, PR 00918

Open in the dashboard

General payments

$351,924

720 records reported · program years 2019–2025

Research payments

$29,733

Paid to them · 23 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,788,539 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Oscar Soto Raices of San Juan, PR is reported in the CMS Open Payments database as having received $351,924 across 720 general payments and $29,733 in research payments paid to them. Separately, studies naming them as principal investigator received $2,788,539 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,352 52
2024 General $34,739 80
2024 Research $4,476 4
2023 General $35,862 82
2023 Research $1,319 1
2022 General $64,103 115
2022 Research $5,959 6
2021 General $22,170 53
2021 Research $5,687 3
2020 General $45,353 102
2020 Research $1,213 3
2019 General $140,344 236
2019 Research $11,080 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Oscar Soto Raices
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Oscar Soto Raices were reported at $9,352. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Oscar Soto Raices Rheumatology median Middle half National median
2019 $140,344 $744 $153–$2,687 $163
2020 $45,353 $462 $98–$2,027 $114
2021 $22,170 $531 $101–$2,153 $132
2022 $64,103 $627 $125–$2,303 $149
2023 $35,862 $741 $145–$2,524 $160
2024 $34,739 $830 $166–$2,660 $164
2025 $9,352 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $176,673 292 payments
  2. AbbVie, Inc. $40,517 88 payments
  3. UCB, Inc. $29,762 62 payments
  4. GlaxoSmithKline, LLC. $28,462 30 payments
  5. Genentech USA, Inc. $16,211 17 payments
  6. Pfizer Inc. $15,106 13 payments
  7. E.R. Squibb & Sons, L.L.C. $13,319 28 payments
  8. Merck Sharp & Dohme Corporation $8,458 12 payments
  9. Eli Lilly Export S.A. Puerto Rico Branch $8,144 33 payments
  10. Horizon Therapeutics plc $4,528 18 payments
  11. Other $10,744 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $203,619 107 payments
  2. Consulting Fee $84,745 35 payments
  3. Travel and Lodging $39,869 119 payments
  4. Food and Beverage $20,745 453 payments
  5. Honoraria $2,700 1 payment
  6. Education $246 5 payments
Products named General payments · program years 2019–2025
  1. TALTZ $121,766 167 payments
  2. OLUMIANT $47,651 31 payments
  3. RINVOQ $32,973 74 payments
  4. BENLYSTA $26,382 21 payments
  5. Bimzelx $22,018 44 payments
  6. XELJANZ $16,771 22 payments
  7. Actemra $16,200 17 payments
  8. ORENCIA $12,081 20 payments
  9. SKYRIZI $9,270 21 payments
  10. RENFLEXIS $8,371 11 payments
  11. Other $13,929 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $17,984 18 payments
  2. Eli Lilly Export S.A. Puerto Rico Branch $11,749 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,433

Median for Rheumatology: 1,511

Drug cost

$1,447,571

Median for Rheumatology: $1,139,948

Branded share of claims

43.5%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cimzia (2 Pack) Certolizumab Pegol Brand 41 $260,551
Humira(Cf) Pen Adalimumab Brand 36 $248,981
Taltz Autoinjector Ixekizumab Brand 36 $247,828
Rinvoq Upadacitinib Brand 32 $208,088
Prolia Denosumab Brand 63 $110,194
Cosentyx Sensoready Pen Secukinumab Brand 14 $104,878
Enbrel Sureclick Etanercept Brand 14 $102,842
Actemra Actpen Tocilizumab Brand 18 $84,447
Otezla Apremilast Brand 12 $57,664
Methotrexate Methotrexate Sodium Brand 321 $5,869

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$34,492

Medicare's payments for the services billed

Medicare patients

45

Average age 75

Services billed

3,836

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 64%
Diabetes 62%
Ischemic heart disease 31%
Chronic kidney disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BENLYSTA
  • GlaxoSmithKline, LLC. $16,853
$16,853 — —
Bimzelx
  • UCB, Inc. $9,569
$9,569 — —
RINVOQ
  • AbbVie, Inc. $2,734
$2,734 32 —
SKYRIZI
  • AbbVie, Inc. $1,839
$1,839 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $373
$373 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

743 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record